PMN
Price
$0.60
Change
+$0.01 (+1.69%)
Updated
Apr 28, 04:54 PM (EDT)
Capitalization
19.23M
22 days until earnings call
SYRE
Price
$14.46
Change
+$0.33 (+2.34%)
Updated
Apr 28, 02:42 PM (EDT)
Capitalization
851.69M
10 days until earnings call
Ad is loading...

PMN vs SYRE

Header iconPMN vs SYRE Comparison
Open Charts PMN vs SYREBanner chart's image
ProMIS Neurosciences
Price$0.60
Change+$0.01 (+1.69%)
Volume$200
Capitalization19.23M
Spyre Therapeutics
Price$14.46
Change+$0.33 (+2.34%)
Volume$700
Capitalization851.69M
PMN vs SYRE Comparison Chart
Loading...
PMN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
PMN vs. SYRE commentary
Apr 28, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PMN is a Hold and SYRE is a StrongBuy.

Ad is loading...
COMPARISON
Comparison
Apr 28, 2025
Stock price -- (PMN: $0.59 vs. SYRE: $14.13)
Brand notoriety: PMN and SYRE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: PMN: 56% vs. SYRE: 52%
Market capitalization -- PMN: $19.23M vs. SYRE: $851.69M
PMN [@Biotechnology] is valued at $19.23M. SYRE’s [@Biotechnology] market capitalization is $851.69M. The market cap for tickers in the [@Biotechnology] industry ranges from $272.78B to $0. The average market capitalization across the [@Biotechnology] industry is $2.13B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PMN’s FA Score shows that 0 FA rating(s) are green whileSYRE’s FA Score has 0 green FA rating(s).

  • PMN’s FA Score: 0 green, 5 red.
  • SYRE’s FA Score: 0 green, 5 red.
According to our system of comparison, both PMN and SYRE are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PMN’s TA Score shows that 6 TA indicator(s) are bullish while SYRE’s TA Score has 4 bullish TA indicator(s).

  • PMN’s TA Score: 6 bullish, 2 bearish.
  • SYRE’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, PMN is a better buy in the short-term than SYRE.

Price Growth

PMN (@Biotechnology) experienced а -7.34% price change this week, while SYRE (@Biotechnology) price change was +11.52% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +11.19%. For the same industry, the average monthly price growth was +1.10%, and the average quarterly price growth was -9.09%.

Reported Earning Dates

PMN is expected to report earnings on Aug 18, 2025.

SYRE is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+11.19% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SYRE($852M) has a higher market cap than PMN($19.2M). PMN has higher P/E ratio than SYRE: PMN (5.35) vs SYRE (1.72). PMN (-37.919) and SYRE (-39.304) have similar YTD gains . PMN has higher annual earnings (EBITDA): -391.76K vs. SYRE (-208.57M). SYRE has more cash in the bank: 603M vs. PMN (21.6M). SYRE has less debt than PMN: SYRE (0) vs PMN (4.05M). PMN (0) and SYRE (0) have equivalent revenues.
PMNSYREPMN / SYRE
Capitalization19.2M852M2%
EBITDA-391.76K-208.57M0%
Gain YTD-37.919-39.30496%
P/E Ratio5.351.72312%
Revenue00-
Total Cash21.6M603M4%
Total Debt4.05M0-
FUNDAMENTALS RATINGS
PMN vs SYRE: Fundamental Ratings
PMN
SYRE
OUTLOOK RATING
1..100
1415
VALUATION
overvalued / fair valued / undervalued
1..100
50
Fair valued
50
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9195
PRICE GROWTH RATING
1..100
9292
P/E GROWTH RATING
1..100
9877
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PMN's Valuation (50) in the null industry is in the same range as SYRE (50) in the Pharmaceuticals Major industry. This means that PMN’s stock grew similarly to SYRE’s over the last 12 months.

PMN's Profit vs Risk Rating (100) in the null industry is in the same range as SYRE (100) in the Pharmaceuticals Major industry. This means that PMN’s stock grew similarly to SYRE’s over the last 12 months.

PMN's SMR Rating (91) in the null industry is in the same range as SYRE (95) in the Pharmaceuticals Major industry. This means that PMN’s stock grew similarly to SYRE’s over the last 12 months.

PMN's Price Growth Rating (92) in the null industry is in the same range as SYRE (92) in the Pharmaceuticals Major industry. This means that PMN’s stock grew similarly to SYRE’s over the last 12 months.

SYRE's P/E Growth Rating (77) in the Pharmaceuticals Major industry is in the same range as PMN (98) in the null industry. This means that SYRE’s stock grew similarly to PMN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
PMNSYRE
RSI
ODDS (%)
Bullish Trend 4 days ago
90%
Bullish Trend 4 days ago
82%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
81%
Bearish Trend 4 days ago
90%
Momentum
ODDS (%)
Bullish Trend 4 days ago
73%
Bullish Trend 4 days ago
81%
MACD
ODDS (%)
Bullish Trend 4 days ago
88%
Bullish Trend 4 days ago
86%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
90%
Bullish Trend 4 days ago
84%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
89%
Advances
ODDS (%)
Bullish Trend 12 days ago
82%
Bullish Trend 5 days ago
85%
Declines
ODDS (%)
Bearish Trend 5 days ago
90%
Bearish Trend 13 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
89%
Bearish Trend 4 days ago
90%
Aroon
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
89%
View a ticker or compare two or three
Ad is loading...
PMN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ACETX10.03N/A
N/A
Invesco Equity and Income Y
PCPAX20.48-0.02
-0.10%
PACE Large Co Value Equity A
SSDAX28.65-0.05
-0.17%
DWS Small Cap Growth A
DGSCX38.81-0.41
-1.05%
Virtus KAR Global Small-Cap Inst
PXSGX28.24-0.53
-1.84%
Virtus KAR Small-Cap Growth I

SYRE and

Correlation & Price change

A.I.dvisor indicates that over the last year, SYRE has been loosely correlated with CGON. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if SYRE jumps, then CGON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SYRE
1D Price
Change %
SYRE100%
-5.36%
CGON - SYRE
53%
Loosely correlated
+3.95%
APGE - SYRE
52%
Loosely correlated
-0.54%
PRME - SYRE
50%
Loosely correlated
-3.43%
ACLX - SYRE
50%
Loosely correlated
-0.41%
IMNM - SYRE
49%
Loosely correlated
-1.41%
More